DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.85
0.00 (0.00%)
Sep 18, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
369.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| Orchestra BioMed Holdings | 31.98M |
| X4 Pharmaceuticals | 15.85M |
| Evommune | 10.00M |
| Ocugen | 4.58M |
DMAC News
- 18 days ago - DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
- 5 weeks ago - DiaMedica Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - DiaMedica Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - DiaMedica Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c) - TheFly
- 5 weeks ago - DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 6 weeks ago - DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
- 2 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire